Present and Future of Personalised Medicine for Endocrine Cancers
Cristina L. Ronchi(University of Birmingham), Barbara Altieri(Universitätsklinikum Würzburg)
Cited by 1
Related Papers
Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study
|The Lancet Diabetes & Endocrinology|2020|247
Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study
|The Lancet Diabetes & Endocrinology|2022|180
Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication
|The Journal of Clinical Endocrinology & Metabolism|2018|119
Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors
|The Journal of Clinical Endocrinology & Metabolism|2017|90
Dlk1 is a novel adrenocortical stem/progenitor cell marker that predicts malignancy in adrenocortical carcinoma
|Cancer Communications|2025|6